Clinical Trial Update: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) [Phase 1]

View source ↗

Summary

A Phase 1 PNOC021 trial of trametinib and everolimus for pediatric and young adult patients with recurrent gliomas has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma
• Low-grade Glioma

Drugs mentioned

• Everolimus (everolimus)
• Trametinib (trametinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma | Phase 1 | Status: SUSPENDED